Posts by Hiroaki Wakimoto, MD, PhD
-
Rare IDH2-mutant Glioma Shares Common Molecular Targets With IDH1-mutant Glioma
Massachusetts General Hospital researchers provide evidence that gene alterations that activate the retinoblastoma and PDGFR pathways have a pivotal biological role in the progression of IDH2-mutant astrocytoma, which is equivalent to progressive IDH1-mutated glioma, and they identified potential drug targets.
-
Novel Approach to Collecting CSF from Preclinical Model Requires No Special Equipment
Kazuhide Shimizu, MD, PhD, and Hiroaki Wakimoto, MD, PhD, of the Department of Neurosurgery, have developed a highly consistent method to collect contaminant-free cerebrospinal fluid from mice that makes use of standard laboratory equipment.
-
Local NAMPT Inhibition Enhances Checkpoint Immunotherapy for Glioblastoma
In a mouse model of glioblastoma, sequential therapy with a nicotinamide phosphoribosyltransferase inhibitor, delivered locally via polymer microparticles, and an immune checkpoint inhibitor improved survival over either agent used as monotherapy.
-
Novel Combination Therapy Highly Effective Against IDH-mutant Glioma
Adding a poly(ADP-ribose) glycohydrolase inhibitor to temozolomide was highly effective in glioma cell lines and an IDH-mutant xenograft mouse model.
-
Combined Blockade of ATR and PARP Effective Against Glioblastoma in Mice
The combination of olaparib and an ATR inhibitor was effective against glioblastoma in mice, providing a much-needed therapeutic breakthrough for this deadly disease.
-
Novel Model of Recurrent Glioblastoma May Facilitate Development of Targeted Therapies
Neurosurgeons and neuro-oncologists at Massachusetts General Hospital have published the first report that documents loss of receptor tyrosine kinase gene amplification in glioblastoma after targeted therapy—and describes a novel preclinical model for studying these molecular changes.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.